Skip to main content
. 2012 Aug 16;7(3):456–465. doi: 10.1111/j.1750-2659.2012.00424.x

Table 3.

Association between selected characteristics and sero‐response proportion (>fourfold‐rise) after vaccination

Category n n (%, 95%CI) Univariate analysis Mutivariate model*
OR (95%CI) P value OR (95%CI) P value
Age (years)
 <62 24 20 (83, 68–98) 1·00 1·00
 62–69 28 23 (82, 68–96) 0·92 (0·22–3·90) 0·91 1·12 (0·18–6·76) 0·91
 70+ 27 14 (52, 33–71) 0·22 (0·06–0·80) 0·02 0·46 (0·09–2·43) 0·36
Trend P = 0·01 Trend P = 0·25
Body mass index (kg/m2)
 <20·2 26 16 (62, 43–81) 0·22 (0·05–0·92) 0·04 0·20 (0·03–1·18) 0·07
 20·2–22·5 28 19 (68, 51–85) 0·29 (0·07–1·22) 0·09 0·36 (0·06–2·10) 0·26
 22·6+ 25 22 (88, 75–100) 1·00 1·00
Trend P = 0·04 Trend P = 0·07
2009/10 seasonal influenza vaccination
 Unvaccinated 48 41 (85, 75–95) 1·00 1·00
 Vaccinated 31 16 (52, 34–70) 0·18 (0·06–0·53) <0·01 0·21 (0·04–1·07) 0·06
Time elapsed between seasonal vaccination and A(H1N1)pdm09 vaccination
 Unvaccinated 48 41 (85, 75–95) 1·00 1·00**
 21 days or more 17 10 (59, 36–82) 0·24 (0·07–0·86) 0·03 0·64 (0·08–5·18) 0·68
 Within 20 days 14 6 (43, 17–69) 0·13 (0·03–0·48) <0·01 0·10 (0·02–0·67) 0·02
Trend P < 0·01 Trend P = 0·01
Prevaccination titer
 <1:10 44 36 (82, 71–93) 1·00 1·00
 1:10–1:20 31 20 (65, 48–82) 0·40 (0·14– 1·17) 0·10 1·04 (0·25–4·35) 0·95
 >1:40 4 1 (25, 0–67) 0·07 (0·01–0·81) 0·03 0·21 (0·02–2·80) 0·24
Trend P = 0·01 Trend P = 0·41
Current treatment for liver disease
 Stronger Neo‐Minophagen C
  No 64 50 (78, 68–88) 1·00 1·00
  Receive 15 7 (47, 22–72) 0·25 (0·08–0·79) 0·02 0·35 (0·07–1·64) 0·18
 Interferon
  No 48 30 (63, 49–77) 1·00 1·00
  Receive 31 27 (87, 75–99) 4·05 (1·22–13·5) 0·02 1·29 (0·28–6·06) 0·75

OR, odds ratio; CI, confidence interval.

*Model included all variables in the table.

**The ORs were obtained from the model in which 2009/10 seasonal influenza vaccination was replaced by time elapsed between seasonal vaccination and A(H1N1)pdm09 vaccination.